This Is An Open-Label Study To Evaluate Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder

Overactive Bladder Clinical Trial

Official title:

A 13-Week, Single-Arm, Open-Label, Multicenter Study To Evaluate Refill Adherence And Satisfaction With Fesoterodine Plus "Your Way" Patient Support Plan In Patients With Symptoms Of Overactive Bladder.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00943735
• Other study ID #: A0221078
• Status: Completed
• Start date: July 2009
• Est. completion date: November 2010

Study information

• Verified date: November 2018
• Source: Pfizer
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The primary objective of the study is to assess the level of medication adherence observed among subjects receiving a specific combination of education and support materials (YourWay plan) along with a prescription for fesoterodine.

Description:

This is a non-interventional, observational study. Study investigators will recruit symptomatic, fesoterodine-naïve subjects when they present with OAB symptoms during regularly-scheduled physician visits fesoterodine-naïve subjects with OAB symptoms present during regularly-scheduled physician visits

Recruitment information / eligibility

• Status: Completed
• Enrollment: 774
• Est. completion date: November 2010
• Est. primary completion date: November 2010
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female outpatients >=18 years old

• Eligible for receiving Toviaz 4mg or 8mg QD treatment based on the approved US label.

Exclusion Criteria:

• Female subjects who are pregnant, lactating, or who are intending to become pregnant within 28 days after the completion of the study (use of contraceptives is not required to participate in the study)

• Have participated in any other studies involving study drugs within 30 days prior to entry in the study

• Subjects who have previously taken fesoterodine.

Related Conditions & MeSH terms

• Overactive Bladder
• Urinary Bladder, Overactive

Intervention

Drug:
• Fesoterodine
Fesoterodine 4 mg and 8 mg QD

Behavioral:
• Your Way
early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Pfizer

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Participants Who Filled at Least 90 Days Supply of Fesoterodine (4mg QD or 8mg QD) Within 90 Days of Study Enrollment	Prototypical pattern for meeting primary endpoint was to fill 3 separate prescriptions (Rx), each for a 30-day supply between enrollment and Day 90. Rx fills could happen as early as Day 0, 30, and 60 of the study period. Participants could also have chosen to wait until their 14-day medication sample was exhausted before receiving their first fill. Investigators received no prescribing restrictions, but were advised not to write Rx for a 90-day supply of fesoterodine at enrollment visit. Participants whose first observed Rx was for a =90-day supply were non-evaluable for the primary endpoint.	Enrollment (Day 0) up to 90 days
Secondary	Percentage of Participants Who Filled at Least One Fesoterodine Prescription During the Study Period (Primary Adherence)	The prototypical pattern was to fill 3 separate prescriptions, each for a 30-day supply, between the enrollment date and Day 90 of the study period; these prescription fills could happen as early as Day 0, 30, and 60 of the study period. Primary adherence was met if the participant filled at least 1 fesoterodine prescription during the study period.	Enrollment (Day 0) up to 90 days
Secondary	Percentage of Participants Who Filled at Least Two Fesoterodine Prescriptions (First Refill) During the Study Period	The prototypical pattern was to fill 3 separate prescriptions, each for a 30-day supply, between the enrollment date and Day 90 of the study period; these prescription fills could happen as early as Day 0, 30, and 60 of the study period. At enrollment, the Investigator provided participants with a prescription for fesoterodine 4mg or 8mg to be filled at a pharmacy of their choice. The first refill indicated that 2 fesoterodine prescriptions had been filled.	Enrollment (Day 0) up to 90 days
Secondary	Percentage of Participants Who Visited the YourWay Website	YourWay plan was available and accessible to all participants prescribed fesoterodine, but was not defined as an explicit or required component. Plan included motivational support for taking fesoterodine and behavioral interventions shown in clinical studies to improve participants' Overactive Bladder (OAB) outcomes. Objectives included intervening quickly after treatment initiation, before participants had an opportunity to discontinue medication, reinforcing the treatable nature of OAB, and setting appropriate expectations for onset of action with therapy and degree of symptom improvement.	Baseline up to 90 days
Secondary	Among Participants Who Used the YourWay Website, the Percentage of Participants Who Agreed That the Website Was Useful		Baseline up to 90 days
Secondary	Percentage of Participants Who Reported Having Read the YourWay Plan Materials Received From Their Physician or From the Resource Kit	YourWay plan included a starter pack with a 14-day supply of 4 mg or 8 mg fesoterodine; guidebook for YourWay plan components and lifestyle modification tips; plan progress tracker with additional lifestyle tips; plan enrollment form. About 1 week after plan enrollment, participants received a resource kit by mail which included: a cover letter; brochures for "Core 4" elements (food and drink, teach your bladder, daily fesoterodine, and track your progress); bladder diary and "track your progress" brochure; and recipes using bladder-friendly foods.	Baseline up to 90 days
Secondary	Percentage of Participants Who Reported Having Adopted Lifestyle Changes to Help Improve Their Overactive Bladder (OAB) Symptoms	The use of the YourWay plan was optional but was available to all participants and included guidance for food and drink choices, bladder training, treatment compliance, and use of a daily tracker.	Baseline up to 90 days
Secondary	Percentage of Participants Who Reported That They Made Bladder-friendly Food and Drink Choices	The use of the YourWay plan was optional but was available to all participants and included bladder-friendly food and drink choices and recipes as well as information for maintaining hydration and avoidance of potential bladder irritants (such as caffeine, citrus fruits and juices, artificial sweeteners, tomato-based foods, soda, alcohol, and spicy foods).	Baseline up to 90 days
Secondary	Percentage of Participants Who Reported That They Trained Their Bladder to "Wait"	The use of the YourWay plan was optional but was available to all participants and included bladder training techniques such as to urinate each day when getting up and before going to bed, gradually increasing the amount of time between urinating, staying with timing goals whether there was a need to urinate or not, and bladder control tips (such as pelvic floor muscle squeeze, sit down and take 5 deep breaths, or stating "I'm the boss - not my bladder").	Baseline up to 90 days
Secondary	Percentage of Participants Who Reported That They Took Toviaz® (Fesoterodine) as Directed		Baseline up to 90 days
Secondary	Percentage of Participants Who Reported That They Recorded Their Treatment Goals in the Daily Core 4 Tracker	YourWay Daily Core 4 Tracker to track daily progress in the 4 core areas of food and drink (make more informed choices), teach your bladder (train your bladder to "wait"), daily Toviaz® (always take as directed), and keep track (share with your doctor).	Baseline up to 90 days
Secondary	Percentage of Participants Who Reported That They Kept Track of Symptoms in the 12 Week Tracker Bladder Diary	For each week, the 12 Week Tracker included a participant determined weekly goal, a reminder to fill the prescription (if appropriate interval), participant reported progress in response to "this week I did well at", and a 7-day Daily Core 4 Tracker checklist (food and drink, teach your bladder, daily fesoterodine, and track your progress).	Baseline up to 90 days
Secondary	Percentage of Participants Who Reported That They Let Their Doctor Know How They Were Doing With the YourWay Plan	Participants were recruited for study participation when they presented with OAB symptoms during regularly-scheduled physician visits; screening and enrollment occurred during the same visit. Follow-up visits could be scheduled per standard clinical practice.	Baseline up to 90 days
Secondary	Percentage of Participants Who Agreed That They Found the YourWay Program Materials Easy to Understand		Baseline up to 90 days
Secondary	Percentage of Participants Who Agreed That the YourWay Program Provided a Good Amount of Information		Baseline up to 90 days
Secondary	Percentage of Participants Who Agreed That the YourWay Plan Provided a Strong Support System That Participants Could Count on for Information and Advice	YourWay participants received 6 telephone calls from an automated speech-recognition system over a period of approximately 11 weeks. The calls included reinforcement of treatment participation, treatment expectations, compliance, general health messages regarding OAB, review of training materials, optional weekly email communication, and a wrap-up call which included a summary of lessons learned from each of the Core 4 lessons calls and guidance to find additional information about medication and lifestyle tips to support management of OAB symptoms.	Baseline up to 90 days
Secondary	Percentage of Participants Who Agreed That They Were Able to Incorporate the YourWay Plan Into Their Lives		Baseline up to 90 days
Secondary	Percentage of Participants Who Agreed That the YourWay Plan Helped Them Play a More Active Role in Managing Their Condition		Baseline up to 90 days
Secondary	Percentage of Participants Who Agreed That They Understood What to Expect From Their OAB Medication, Toviaz® (Fesoterodine)	Product indication and safety information was provided to all participants by the investigator and / or within the YourWay plan program information.	Baseline up to 90 days
Secondary	Percentage of Participants Who Agreed That They Learned Something About Their Condition		Baseline up to 90 days
Secondary	Percentage of Participants Who Agreed That They Increased Their Knowledge of Healthy Bladder Behaviors	The use of the YourWay plan was optional but was available to all participants and included healthy bladder behaviors such as setting and maintaining personal goals and choice of bladder-friendly food and drinks.	Baseline up to 90 days
Secondary	Percentage of Participants Who Agreed That They Understand OAB is a Chronic Condition That Can be Successfully Managed, But Generally Not Cured		Baseline up to 90 days
Secondary	Percentage of Participants Who Reported They Felt Confident That They Could Manage Their OAB as a Result of the YourWay Plan		Baseline up to 90 days
Secondary	Percentage of Participants Who Reported They Were Satisfied With the Overall Content of the YourWay Plan		Baseline up to 90 days
Secondary	Percentage of Participants Who Reported They Were Satisfied With the Participant Support Telephone Calls	YourWay participants received 6 telephone calls from an automated speech-recognition system over a period of approximately 11 weeks. The calls included reinforcement of treatment participation, treatment expectations, compliance, general health messages regarding OAB, review of training materials, optional weekly email communication, and a wrap-up call which included a summary of lessons learned from each of the Core 4 lessons calls and guidance to find additional information about medication and lifestyle tips to support management of OAB symptoms.	Baseline up to 90 days
Secondary	Percentage of Participants Who Reported They Were Satisfied With the Treatment Goals and Bladder Symptoms Progress Trackers	Treatment goals and bladder symptoms progress trackers were incorporated in the 12 Week Tracker which included a participant determined weekly goal, a reminder to fill the prescription (if appropriate interval), participant reported progress in response to "this week I did well at", and a 7-day Daily Core 4 Tracker checklist (food and drink, teach your bladder, daily fesoterodine, and track your progress).	Baseline up to 90 days
Secondary	Percentage of Participants Who Reported They Were Satisfied With Their Physician		Baseline up to 90 days
Secondary	Percentage of Participants Who Reported the YourWay Plan Encouraged Their Use of Toviaz® (Fesoterodine)		Baseline up to 90 days
Secondary	Percentage of Participants Who Agreed That They Had a Good Understanding About Their Condition and How to Treat it		Baseline up to 90 days
Secondary	Comparison of Percentage of Participants Who Agreed That They Had a Good Understanding About Their Condition and How to Treat it, Between Enrollment Date and End of Study CATI Interview		Enrollment (Day 0) up to 90 days

External Links

•   To obtain contact information for a study center near you, click here.